Statistical remedies for medical researchers

por Thall, Peter F
Publicado 2020

Interpreting Randomized Controlled Trials

por Msaouel, Pavlos, Lee, Juhee, Thall, Peter F.
Publicado 2023

Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes

por Msaouel, Pavlos, Lee, Juhee, Thall, Peter F.
Publicado 2021

A Causal Framework for Making Individualized Treatment Decisions in Oncology

por Msaouel, Pavlos, Lee, Juhee, Karam, Jose A., Thall, Peter F.
Publicado 2022

BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials

por Jiang, Liyun, Thall, Peter F, Yan, Fangrong, Kopetz, Scott, Yuan, Ying
Publicado 2023

Bayesian treatment comparison using parametric mixture priors computed from elicited histograms

por Thall, Peter F, Ursino, Moreno, Baudouin, Véronique, Alberti, Corinne, Zohar, Sarah
Publicado 2017

Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials

por Le-Rademacher, Jennifer G., Hillman, Shauna, Storrick, Elizabeth, Mahoney, Michelle R., Thall, Peter F., Jatoi, Aminah, Mandrekar, Sumithra J.
Publicado 2020

Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial

por Sandberg, David I., Rytting, Michael, Zaky, Wafik, Kerr, Marcia, Ketonen, Leena, Kundu, Uma, Moore, Bartlett D., Yang, Grace, Hou, Ping, Sitton, Clark, Cooper, Laurence J., Gopalakrishnan, Vidya, Lee, Dean A., Thall, Peter F., Khatua, Soumen
Publicado 2015

PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies

por Qazilbash, Muzaffar H., Wieder, Eric, Thall, Peter F., Wang, Xuemei, Rios, Rosa, Lu, Sijie, Kanodia, Shreya, Ruisaard, Kathryn E., Giralt, Sergio A., Estey, Elihu H., Cortes, Jorge, Komanduri, Krishna V., Clise-Dwyer, Karen, Alatrash, Gheath, Ma, Qing, Champlin, Richard E., Molldrem, Jeffrey J.
Publicado 2016

Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS

por Gladstone, Douglas E, D'Alessio, Franco, Howard, Christopher, Lyu, Mi-Ae, Mock, Jason R., Gibbs, Kevin W., Abrams, Darryl, Huang, Meixian, Zeng, Ke, Herlihy, James P., Castillo, Sergio T., Bassett, Roland, Sadeghi, Tara, Parmar, Simrit, Flowers, Christopher R., Mukherjee, Siddhartha, Schoenfeld, David, Thall, Peter F., Slutsky, Arthur S.
Publicado 2023

High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients

por Greenbaum, Uri, Klein, Kimberly, Martinez, Fernando, Song, Juhee, Thall, Peter F., Ramdial, Jeremy L., Knape, Cristina, Aung, Fleur M., Scroggins, Jamie, Knopfelmacher, Adriana, Mulanovich, Victor, Borjan, Jovan, Adachi, Javier, Muthu, Mayoora, Leung, Cerena, Medina, Mayrin Correa, Champlin, Richard, Olson, Amanda, Alousi, Amin, Rezvani, Katayoun, Shpall, Elizabeth J.
Publicado 2021

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation

por Konopleva, Marina, Benton, Christopher B., Thall, Peter F., Zeng, Zhihong, Shpall, Elizabeth, Ciurea, Stefan, Kebriaei, Partow, Alousi, Amin, Popat, Uday, Anderlini, Paolo, Nieto, Yago, Parmar, Simrit, Qiao, Wei, Chen, Julianne, Rondon, Gabriela, McMullin, Becky, Wang, Rui-Yu, Lu, Hongbo, Schober, Wendy, Woodworth, Glenda, Gulbis, Alison, Cool, Rita, Andreeff, Michael, Champlin, Richard
Publicado 2015

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation

por Andersson, Borje S., Thall, Peter F., Ma, Junsheng, Valdez, Benigno C., Bassett, Roland, Chen, Julianne, Ahmed, Sairah, Alousi, Amin, Bashir, Qaiser, Ciurea, Stefan, Gulbis, Alison, Cool, Rita, Kawedia, Jitesh, Hosing, Chitra, Kebriaei, Partow, Kornblau, Steve, Myers, Alan, Oran, Betul, Rezvani, Katayoun, Shah, Nina, Shpall, Elizabeth, Parmar, Simrit, Popat, Uday R., Nieto, Yago, Champlin, Richard E.
Publicado 2022

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients

por Andersson, Borje S., Thall, Peter F., Valdez, Benigno C., Milton, Denái R., Al-Atrash, Gheath, Chen, Julianne, Gulbis, Alison, Chu, Diem, Martinez, Charles, Parmar, Simrit, Popat, Uday, Nieto, Yago, Kebriaei, Partow, Alousi, Amin, de Lima, Marcos, Rondon, Gabriela, Meng, Qing H., Myers, Alan, Kawedia, Jitesh, Worth, Laura L., Fernandez-Vina, Marcelo, Madden, Timothy, Shpall, Elizabeth J., Jones, Roy B., Champlin, Richard E.
Publicado 2016